About this data
What it is
ClinicalTrials.gov is the US registry of clinical studies. Drug and device makers register their trials there and update the record as each study moves on. We list the studies that companies sponsor, and match the sponsor to a public company when the name lines up. The page opens on Phase 3 studies marked completed, the late-stage trials that come before a request for approval. Change View to see the changes of status we have noticed, or every recent update.
Who files it
The sponsor of the study, in its record on ClinicalTrials.gov. The registry is run by the US National Library of Medicine and does not check what sponsors report.
How current
We check the registry every day. Sponsors update records on their own schedule, from the same week to months later, so a change can appear in the registry well after it happened.
Terms
ClinicalTrials.govClinicalTrials.gov is the US government's registry of clinical studies, run by the National Library of Medicine. Sponsors register a study before it starts and update the record as it goes. The registry does not check what a sponsor reports.Phase 3The late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages.statusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time).completedThe sponsor has marked the study as finished. It says nothing about whether the treatment worked: results, if any, are reported separately and often later.status changesOur history of status changes starts the day we first stored each study, so a change made before that is not shown. The date is when we noticed the change, which can be later than when the sponsor made it.primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update.company matchWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private.
Worth knowing
A completed study is not a result: the registry says the study ended, not whether the treatment worked. Status changes start on the day we first stored each study, so earlier changes are not shown. Dates are the sponsor's own, and an estimated date can pass without an update. We match sponsors to companies automatically, with a hand-checked list for the large drugmakers, so a study with no ticker may still belong to a public company. This is information about studies, not a forecast of what they will show or of a stock's price.
Not to be confused with
FDA approvals and clearances: what the FDA decided, not what a sponsor reports about a study.

All of this comes from ClinicalTrials.gov, the US registry of clinical studies. We are not affiliated with it.

Studies updated per day, last 30 days

0200400600Oct 17 · All industry-sponsored studies: 0Oct 17 · Sponsor matched to a public company: 0Oct 17Oct 18 · All industry-sponsored studies: 0Oct 18 · Sponsor matched to a public company: 0Oct 19 · All industry-sponsored studies: 238Oct 19 · Sponsor matched to a public company: 79Oct 20 · All industry-sponsored studies: 278Oct 20 · Sponsor matched to a public company: 92Oct 21 · All industry-sponsored studies: 244Oct 21 · Sponsor matched to a public company: 78Oct 21Oct 22 · All industry-sponsored studies: 234Oct 22 · Sponsor matched to a public company: 67Oct 23 · All industry-sponsored studies: 259Oct 23 · Sponsor matched to a public company: 93Oct 24 · All industry-sponsored studies: 0Oct 24 · Sponsor matched to a public company: 0Oct 25 · All industry-sponsored studies: 0Oct 25 · Sponsor matched to a public company: 0Oct 25Oct 26 · All industry-sponsored studies: 253Oct 26 · Sponsor matched to a public company: 70Oct 27 · All industry-sponsored studies: 283Oct 27 · Sponsor matched to a public company: 102Oct 28 · All industry-sponsored studies: 287Oct 28 · Sponsor matched to a public company: 97Oct 29 · All industry-sponsored studies: 256Oct 29 · Sponsor matched to a public company: 88Oct 29Oct 30 · All industry-sponsored studies: 252Oct 30 · Sponsor matched to a public company: 103Oct 31 · All industry-sponsored studies: 0Oct 31 · Sponsor matched to a public company: 0Nov 1 · All industry-sponsored studies: 0Nov 1 · Sponsor matched to a public company: 0Nov 2 · All industry-sponsored studies: 305Nov 2 · Sponsor matched to a public company: 99Nov 2Nov 3 · All industry-sponsored studies: 478Nov 3 · Sponsor matched to a public company: 257Nov 4 · All industry-sponsored studies: 390Nov 4 · Sponsor matched to a public company: 184Nov 5 · All industry-sponsored studies: 356Nov 5 · Sponsor matched to a public company: 143Nov 6 · All industry-sponsored studies: 338Nov 6 · Sponsor matched to a public company: 135Nov 6Nov 7 · All industry-sponsored studies: 0Nov 7 · Sponsor matched to a public company: 0Nov 8 · All industry-sponsored studies: 0Nov 8 · Sponsor matched to a public company: 0Nov 9 · All industry-sponsored studies: 309Nov 9 · Sponsor matched to a public company: 101Nov 10 · All industry-sponsored studies: 347Nov 10 · Sponsor matched to a public company: 139Nov 10Nov 11 · All industry-sponsored studies: 0Nov 11 · Sponsor matched to a public company: 0Nov 12 · All industry-sponsored studies: 576Nov 12 · Sponsor matched to a public company: 214Nov 13 · All industry-sponsored studies: 329Nov 13 · Sponsor matched to a public company: 136Nov 14 · All industry-sponsored studies: 0Nov 14 · Sponsor matched to a public company: 0Nov 14Nov 15 · All industry-sponsored studies: 0Nov 15 · Sponsor matched to a public company: 0
0200400600Oct 17 · All industry-sponsored studies: 0Oct 17 · Sponsor matched to a public company: 0Oct 17Oct 18 · All industry-sponsored studies: 0Oct 18 · Sponsor matched to a public company: 0Oct 19 · All industry-sponsored studies: 238Oct 19 · Sponsor matched to a public company: 79Oct 20 · All industry-sponsored studies: 278Oct 20 · Sponsor matched to a public company: 92Oct 21 · All industry-sponsored studies: 244Oct 21 · Sponsor matched to a public company: 78Oct 21Oct 22 · All industry-sponsored studies: 234Oct 22 · Sponsor matched to a public company: 67Oct 23 · All industry-sponsored studies: 259Oct 23 · Sponsor matched to a public company: 93Oct 24 · All industry-sponsored studies: 0Oct 24 · Sponsor matched to a public company: 0Oct 25 · All industry-sponsored studies: 0Oct 25 · Sponsor matched to a public company: 0Oct 25Oct 26 · All industry-sponsored studies: 253Oct 26 · Sponsor matched to a public company: 70Oct 27 · All industry-sponsored studies: 283Oct 27 · Sponsor matched to a public company: 102Oct 28 · All industry-sponsored studies: 287Oct 28 · Sponsor matched to a public company: 97Oct 29 · All industry-sponsored studies: 256Oct 29 · Sponsor matched to a public company: 88Oct 29Oct 30 · All industry-sponsored studies: 252Oct 30 · Sponsor matched to a public company: 103Oct 31 · All industry-sponsored studies: 0Oct 31 · Sponsor matched to a public company: 0Nov 1 · All industry-sponsored studies: 0Nov 1 · Sponsor matched to a public company: 0Nov 2 · All industry-sponsored studies: 305Nov 2 · Sponsor matched to a public company: 99Nov 2Nov 3 · All industry-sponsored studies: 478Nov 3 · Sponsor matched to a public company: 257Nov 4 · All industry-sponsored studies: 390Nov 4 · Sponsor matched to a public company: 184Nov 5 · All industry-sponsored studies: 356Nov 5 · Sponsor matched to a public company: 143Nov 6 · All industry-sponsored studies: 338Nov 6 · Sponsor matched to a public company: 135Nov 6Nov 7 · All industry-sponsored studies: 0Nov 7 · Sponsor matched to a public company: 0Nov 8 · All industry-sponsored studies: 0Nov 8 · Sponsor matched to a public company: 0Nov 9 · All industry-sponsored studies: 309Nov 9 · Sponsor matched to a public company: 101Nov 10 · All industry-sponsored studies: 347Nov 10 · Sponsor matched to a public company: 139Nov 10Nov 11 · All industry-sponsored studies: 0Nov 11 · Sponsor matched to a public company: 0Nov 12 · All industry-sponsored studies: 576Nov 12 · Sponsor matched to a public company: 214Nov 13 · All industry-sponsored studies: 329Nov 13 · Sponsor matched to a public company: 136Nov 14 · All industry-sponsored studies: 0Nov 14 · Sponsor matched to a public company: 0Nov 14Nov 15 · All industry-sponsored studies: 0Nov 15 · Sponsor matched to a public company: 0

All industry-sponsored studies Sponsor matched to a public company

By the day the sponsor last updated the study's record. A study updated twice counts once, on its latest day.

Latest clinical trial updates

Reset

Showing: ticker RGNX · All recent updates

Studies by the date their record was last updated.

Latest clinical trial updates
UpdatedStudySponsorWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private.PhaseThe late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages.StatusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time).EnrolledPrimary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update.Source
Aug 19, 2026Long-term Follow-Up for RGX-121
NCT04597385 · Mucopolysaccharidosis II
Long-term Follow-Up
RGNX
Regenxbio Inc.
—Active, not recruiting27Oct 2028Registry ↗
Jul 21, 2026AFFINITY DUCHENNE: RGX-202 Gene Therapy in Participants With Duchenne Muscular Dystrophy (DMD)
NCT05693142 · Duchenne Muscular Dystrophy
RGX-202
RGNX
Regenxbio Inc.
Phase 2/3Active, not recruiting65Sep 2026Registry ↗
Jul 7, 2026AFFINITY BEYOND: Anti-AAV8 Antibody Assessment Study of Males With DMD
NCT05683379 · Duchenne Muscular Dystrophy
AAV8 DetectCDx
RGNX
Regenxbio Inc.
—Active, not recruiting200Jun 30, 2026Registry ↗
Jun 17, 2026Expanded Access to RGX-202
NCT07652606
RGX-202
RGNX
Regenxbio Inc.
—Temporarily not available——Registry ↗
Jun 4, 2026RGX-121-3102 Gene Therapy in Participants With MPS II (Hunter Syndrome)
NCT07236606 · MPS II, Hunter Syndrome (MPS II)
RGX-121-3102
RGNX
Regenxbio Inc.
Phase 3Active, not recruiting2Apr 30, 2028Registry ↗
Apr 29, 2026Long Term Follow-Up for RGX-111
NCT06103487 · Mucopolysaccharidosis I
No Intervention
RGNX
Regenxbio Inc.
—Enrolling by invitation21Sep 2027Registry ↗
Mar 24, 2026Long Term Follow-up for RGX-202
NCT06491927 · Duchenne Muscular Dystrophy
No Intervention
RGNX
Regenxbio Inc.
—Enrolling by invitation66Dec 1, 2029Registry ↗
Mar 12, 2026RGX-111 Gene Therapy in Patients With MPS I
NCT03580083 · Mucopolysaccharidosis Type I (MPS I), Hurler Syndrome
RGX-111
RGNX
Regenxbio Inc.
Phase 1/2Suspended21Jul 7, 2027Registry ↗
Jan 28, 2025RGX-121 Gene Therapy in Children 5 Years of Age and Over With MPS II (Hunter Syndrome)
NCT04571970 · Mucopolysaccharidosis Type II (MPS II)
RGX-121
RGNX
Regenxbio Inc.
Phase 1/2Completed6May 9, 2023Registry ↗
Jan 28, 2025CAMPSIITE™ RGX-121 Gene Therapy in Subjects With MPS II (Hunter Syndrome)
NCT03566043 · Mucopolysaccharidosis Type II (MPS II)
RGX-121
RGNX
Regenxbio Inc.
Phase 2/3Active, not recruiting48Nov 27, 2023Registry ↗
Jul 13, 2023A Gene Therapy Study for Homozygous Familial Hypercholesterolemia (HoFH)
NCT02651675 · Homozygous Familial Hypercholesterolemia (HoFH)
AAV directed hLDLR gene therapy
RGNX
Regenxbio Inc.
Phase 1/2Terminated9Nov 27, 2020Registry ↗
May 16, 2023Safety and Tolerability of RGX-314 (Investigational Product) Gene Therapy for Neovascular AMD Trial
NCT03066258 · Neovascular Age-related Macular Degeneration, Wet Age-relat…
RGX-314
RGNX
Regenxbio Inc.
Phase 1/2Completed42Nov 24, 2019Registry ↗
Mar 9, 2023A Long-term Follow-up Study to Evaluate the Safety and Efficacy of RGX-501
NCT04080050 · Homozygous Familial Hypercholesterolemia (HoFH)
Single intravenous (IV) dose of human Low Density Lipoprote…
RGNX
Regenxbio Inc.
—Unknown8Sep 29, 2024Registry ↗
Oct 10, 2022Mucopolysaccharidosis Type II Observational
NCT04591834 · Mucopolysaccharidosis II
Observational
RGNX
Regenxbio Inc.
—Withdrawn0Jul 2025Registry ↗
Apr 26, 2022Mucopolysaccharidosis Type II Natural History
NCT03529786 · Mucopolysaccharidosis II
RGNX
Regenxbio Inc.
—Completed36Mar 22, 2022Registry ↗
Nov 1, 2021A Retrospective, Natural History Study in Children With CLN2
NCT04480476 · Late-infantile Neuronal Ceroid Lipofuscinosis Type 2 (CLN2)
RGNX
Regenxbio Inc.
—Withdrawn0Apr 2022Registry ↗
Nov 1, 2021An Observational Study in Children With CLN2 Batten Disease
NCT04462692 · Neuronal Ceroid Lipofuscinosis Type 2 (CLN2)
RGNX
Regenxbio Inc.
—Withdrawn0Oct 2023Registry ↗
Feb 2, 2021Identifying and Genotyping Homozygous Familial Hypercholesterolemia (HoFH) Patients
NCT04148001 · Homozygous Familial Hypercholesterolemia (HoFH)
RGNX
Regenxbio Inc.
—Completed4Apr 8, 2020Registry ↗

18 items, most recent first (up to 50). Each row links to the study's page on ClinicalTrials.gov. Updated Nov 15, 2026, 8:16 PM EST.

Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.

Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · FDA approvals and clearances